BYOT Byotrol Plc

    


Byotrol plc



The Directors of Byotrol plc (the "Company") are pleased to announce the outcome
of a six month study conducted at the Glasgow Royal Infirmary to measure the
efficacy of the Company's anti-microbial technology in combating the spread of
Methicillin Resistant Staphylococcus Aureus ("MRSA") within a working hospital
ward environment.

The study was staged in two ward areas with Vascular Surgery at Glasgow Royal
Infirmary which because of the nature of conditions and patients treated had a
potential for high incidence of MRSA infection. One of the wards was cleaned
with Byotrol and the other with existing cleaning agents.

The independently supervised study showed that daily cleaning with Byotrol's
patented biocide of the ward's high contact surfaces, including door handles,
tables, television handsets, patient contact systems and bed rails, representing
a small fraction of the total surfaces within the ward, resulted in a
significant reduction in the incidence of MRSA.

The cleaning regimen, which required no special equipment or extra resource, was
practised for 4 months and the incidence of MRSA was shown to have been reduced
by 75% against the pre-trial condition of the ward. During this phase there were
test periods with no incidence of MRSA.

Furthermore, the number of hospital acquired cases of MRSA was seen to be 50%
higher in the area of the ward where a conventional disinfectant was used
compared to that where Byotrol was used. This was achieved as a result of
Byotrol's residual action on surfaces against micro-organisms even after it has
dried.

The study was independently supervised by Professor Curtis Gemmell, Professor of
Bacterial Infection and Epidemiology at the University of Glasgow who worked
closely with the hospital's Vascular Surgery team. Professor Gemmell is also a
director of the Scottish Methicillin Resistant Staphylococcus Aureus (MRSA)
Reference Laboratory and an appointed adviser to Byotrol on the requirements of
the NHS and control of infection in healthcare.

Professor Gemmell will today be presenting a paper based on the study to medical
and infection control professionals at the 6th international conference of the
Hospital Infection Society in the Netherlands.

Stephen Falder, Byotrol's Deputy Chairman commented:

"This independent study has demonstrated the outstanding effectiveness of
Byotrol in a working hospital environment. Byotrol was used by the existing
cleaning staff, with no risk or disturbance to patients or healthcare
professionals and with no requirement for expensive equipment. The Directors
believe that the results of the study further pave the way for the Company to
achieve significant sales into the healthcare sector."

Financial calls to:

Stephen Falder                          07767 404629
Deputy Chairman                         0161 277 9518
Byotrol plc

David McRobbie                          07739 549226
Chief Executive
Byotrol plc

Charles Stanley Securities              020 7149 6457
Philip Davies

Media Calls to:

Allan Piper                             0207 436 7486
First City PR

Jim Rothnie
McCann Erickson PR                      01625 822540

Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Lug 2023 a Lug 2024